OrbiMed’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $54.7M | Buy |
1,946,500
+293,600
| +18% | +$7.82M | 1.08% | 28 |
|
|
2025
Q4 | $41.2M | Buy |
+1,652,900
| New | +$41.7M | 0.84% | 38 |
|
|
2025
Q2 | – | Sell |
-3,850,200
| Closed | -$97.6M | – | 113 |
|
|
2025
Q1 | $97.6M | Buy |
+3,850,200
| New | +$101M | 2.33% | 13 |
|
|
2023
Q1 | – | Sell |
-1,393,600
| Closed | -$71.4M | – | 135 |
|
|
2022
Q4 | $71.4M | Sell |
1,393,600
-1,205,400
| -46% | -$57.8M | 1.37% | 26 |
|
|
2022
Q3 | $114K | Sell |
2,599,000
-145,000
| -5% | -$7.05M | 2.11% | 9 |
|
|
2022
Q2 | $144K | Sell |
2,744,000
-1,161,500
| -30% | -$59.2M | 2.61% | 9 |
|
|
2022
Q1 | $202M | Buy |
3,905,500
+1,290,100
| +49% | +$66.9M | 3.28% | 4 |
|
|
2021
Q4 | $154M | Buy |
+2,615,400
| New | +$130M | 1.99% | 9 |
|
|
2021
Q1 | – | Sell |
-3,616,600
| Closed | -$133M | – | 174 |
|
|
2020
Q4 | $133M | Buy |
+3,616,600
| New | +$133M | 1.16% | 21 |
|
|
2020
Q2 | – | Sell |
-3,174,753
| Closed | -$98.3M | – | 148 |
|
|
2020
Q1 | $98.3M | Buy |
+3,174,753
| New | +$108M | 1.65% | 22 |
|
|
2019
Q1 | – | Sell |
-634,719
| Closed | -$26.3M | – | 137 |
|
|
2018
Q4 | $26.3M | Sell |
634,719
-70,091
| -10% | -$2.91M | 0.49% | 60 |
|
|
2018
Q3 | $29.5M | Sell |
704,810
-330,218
| -32% | -$12.7M | 0.36% | 73 |
|
|
2018
Q2 | $35.6M | Hold |
1,035,028
| – | – | 0.42% | 64 |
|
|
2018
Q1 | $34.9M | Hold |
1,035,028
| – | – | 0.43% | 63 |
|
|
2017
Q4 | $35.6M | Sell |
1,035,028
-1,556,547
| -60% | -$53.1M | 0.45% | 63 |
|
|
2017
Q3 | $87.8M | Hold |
2,591,575
| – | – | 0.84% | 36 |
|
|
2017
Q2 | $82.6M | Sell |
2,591,575
-3,106,454
| -55% | -$98M | 0.87% | 38 |
|
|
2017
Q1 | $185M | Buy |
5,698,029
+251,062
| +5% | +$7.92M | 2.1% | 12 |
|
|
2016
Q4 | $168M | Buy |
5,446,967
+1,724,028
| +46% | +$52.6M | 2.14% | 13 |
|
|
2016
Q3 | $120M | Sell |
3,722,939
-749,921
| -17% | -$25.1M | 1.36% | 25 |
|
|
2016
Q2 | $149M | Buy |
4,472,860
+128,272
| +3% | +$4.09M | 1.56% | 21 |
|
|
2016
Q1 | $122M | Sell |
4,344,588
-2,108
| -0% | -$60.2K | 1.29% | 28 |
|
|
2015
Q4 | $133M | Buy |
4,346,696
+380,494
| +10% | +$12M | 1.21% | 28 |
|
|
2015
Q3 | $118M | Buy |
3,966,202
+748,340
| +23% | +$24M | 1.19% | 27 |
|
|
2015
Q2 | $102M | Buy |
3,217,862
+72,726
| +2% | +$2.37M | 0.86% | 35 |
|
|
2015
Q1 | $104M | Buy |
3,145,136
+237,150
| +8% | +$7.54M | 0.89% | 34 |
|
|
2014
Q4 | $85.9M | Buy |
2,907,986
+93,806
| +3% | +$2.69M | 0.82% | 36 |
|
|
2014
Q3 | $79M | Sell |
2,814,180
-1,488,248
| -35% | -$41.8M | 0.82% | 36 |
|
|
2014
Q2 | $121M | Buy |
4,302,428
+443,734
| +11% | +$12.6M | 1.42% | 28 |
|
|
2014
Q1 | $118M | Buy |
3,858,694
+113,832
| +3% | +$3.39M | 1.45% | 24 |
|
|
2013
Q4 | $109M | Sell |
3,744,862
-482,100
| -11% | -$14M | 1.6% | 21 |
|
|
2013
Q3 | $115M | Sell |
4,226,962
-941,116
| -18% | -$25.6M | 2.06% | 15 |
|
|
2013
Q2 | $137M | Buy |
+5,168,078
| New | +$143M | 2.91% | 9 |
|
Other funds holding PFE
VCM
VPM
OrbiMed's PFE Position: Q1 2026 in Review
OrbiMed increased its Pfizer (PFE) stake by 18% in Q1 2026, buying an estimated $7.82M and bringing the position to 1,946,500 shares worth $54.7M. The position accounts for 1.08% of the portfolio, ranked #28.
OrbiMed first reported a position in PFE in Q2 2013 and has held it in 33 quarters since. The position peaked at $202M in Q1 2022. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- OrbiMed held 1,946,500 shares of Pfizer worth $54.7M as of Q1 2026.
- OrbiMed bought 293,600 Pfizer shares in Q1 2026, an estimated $7.82M.
- Pfizer made up 1.08% of OrbiMed's portfolio in Q1 2026, its #28 holding.
- OrbiMed first reported a position in Pfizer in Q2 2013 and has held it in 33 quarters since.
- OrbiMed's Pfizer position peaked at $202M in Q1 2022.
- 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.